Complementing these findings, a recent prospective study demonstrated that dynamic changes in C-reactive protein (CRP), another key systemic inflammatory marker, served as a robust prognostic indicator in melanoma patients receiving immunotherapy, further supporting the clinical value of serial inflammatory marker monitoring for predicting treatment outcomes (38). Here, CRP is linked to melanoma.